{"schema_version":"secwatch.filing_event.v1","accession":"0001493152-25-017007","form_type":"8-K","ticker":"HROW","cik":"0001360214","company_name":"HARROW, INC.","filed_at":"2025-10-06T23:59:59+00:00","discovered_at":"2026-05-14T18:02:39.226072+00:00","generated_at":"2026-05-17T04:33:29.599218+00:00","sec_items":["5.02","7.01","9.01"],"event_type":"leadership","sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"confidence":"high","headline":"ImprimisRx (Harrow subsidiary) appoints Frank Mullery as CEO; prior CEO John Saharek transitions out","bullets":["John Saharek ceased as President/CEO of ImprimisRx effective Oct 6, 2025; transitions to non-officer role with no new compensation.","Frank Mullery appointed CEO of ImprimisRx; previously President of Sintetica US and led Mylan Institutional to >$1B revenue.","Bridseida Cruz appointed Head of Quality; over 25 years experience in FDA remediation and operational improvement.","No compensatory arrangements entered with Saharek in connection with transition."],"urls":{"canonical":"https://secwatch.observer/filing/0001493152-25-017007","json":"https://secwatch.observer/filing/0001493152-25-017007.json","markdown":"https://secwatch.observer/filing/0001493152-25-017007.md","text":"https://secwatch.observer/filing/0001493152-25-017007.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1360214/000149315225017007/0001493152-25-017007-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1360214/000149315225017007/form8-k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-17T04:33:29.599218+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}